Retail Investors Among Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) Largest Stockholders and Were Hit After Last Week's 9.5% Price Drop
Retail Investors Among Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) Largest Stockholders and Were Hit After Last Week's 9.5% Price Drop
Key Insights
主要見解
- Significant control over Joinn Laboratories(China)Co.Ltd by retail investors implies that the general public has more power to influence management and governance-related decisions
- The top 13 shareholders own 50% of the company
- 39% of Joinn Laboratories(China)Co.Ltd is held by insiders
- 零售投資者對昭衍新藥(中國)有限公司擁有重要的控制權,這意味着普通公衆對管理和治理相關決策有更大的影響力。
- 前13名股東佔該公司50%的股份。
- 昭衍新藥(中國)有限公司39%的股份由內部人士持有。
A look at the shareholders of Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are retail investors with 42% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
看一下昭衍新藥(中國)有限公司(SHSE:603127)的股東,我們可以了解哪個群體更具影響力。持有最大股份的是零售投資者,擁有42%的所有權。換句話說,該群體面臨着最大的上行潛力(或下行風險)。
Following a 9.5% decrease in the stock price last week, retail investors suffered the most losses, but insiders who own 39% stock also took a hit.
上週股價下跌了9.5%,零售投資者遭受最大損失,但持有39%股份的內部人員也受到打擊。
In the chart below, we zoom in on the different ownership groups of Joinn Laboratories(China)Co.Ltd.
在下面的圖表中,我們將聚焦昭衍新藥(中國)有限公司的不同所有權群體。
![1724397431521](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240823/42780817-0-3288593da683023c71b19ee6ed346be8.webp/bigjpg)
What Does The Institutional Ownership Tell Us About Joinn Laboratories(China)Co.Ltd?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
機構投資者通常將自己的回報與常見的指數回報進行比較。因此,他們通常會考慮購買包括在相關基準指數中的較大公司。
As you can see, institutional investors have a fair amount of stake in Joinn Laboratories(China)Co.Ltd. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Joinn Laboratories(China)Co.Ltd's historic earnings and revenue below, but keep in mind there's always more to the story.
正如您所見,機構投資者在昭衍新藥(中國)有限公司中持有相當大比例的股份。這表明在專業投資者中有一定的可信度。但我們不能僅僅依靠這一事實,因爲機構有時也會做出糟糕的投資決策,就像每個人都有可能犯錯一樣。當多家機構持有某隻股票時,總會存在它們在一個「擁擠交易」的風險。當這樣的交易出錯時,多方可能會爭相快速賣出股票。這種風險在沒有增長曆史的公司中更高。您可以在下面看到昭衍新藥(中國)有限公司的歷史盈利和營業收入,但請記住故事還有更多內容。
![1724397432964](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240823/42780817-1-07f30fc19e59b63e5175cc7bf188ca4d.webp/bigjpg)
Hedge funds don't have many shares in Joinn Laboratories(China)Co.Ltd. Our data suggests that Yuxia Feng, who is also the company's Top Key Executive, holds the most number of shares at 22%. When an insider holds a sizeable amount of a company's stock, investors consider it as a positive sign because it suggests that insiders are willing to have their wealth tied up in the future of the company. Zhi Wen Zhou is the second largest shareholder owning 10% of common stock, and Zhong Ou Fund Management Co., Ltd holds about 3.2% of the company stock.
對沖基金在昭衍新藥(中國)有限公司的持股不多。我們的數據表明,馮玉俠,也是公司的最高主要執行官,持有公司22%的股份。當內部人士持有公司的大量股票時,投資者會認爲這是一個積極的跡象,因爲這表明內部人士願意將自己的財富綁定在公司的未來。 周之文是第二大股東,擁有10%的普通股,而中歐基金管理有限公司持有公司股票的大約3.2%。
Looking at the shareholder registry, we can see that 50% of the ownership is controlled by the top 13 shareholders, meaning that no single shareholder has a majority interest in the ownership.
通過查看股東登記表,我們可以看到前13大股東控制了50%的所有權,這意味着沒有單個股東擁有多數股權。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
研究機構持股比例是衡量和篩選股票預期表現的好方法。同樣可以通過研究分析師情緒來實現。由於相當多的分析師都關注着該股票,因此你可以很容易地研究預測的增長。
Insider Ownership Of Joinn Laboratories(China)Co.Ltd
昭衍新藥(中國)有限公司的內部股權
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
在不同國家,內部人員的定義可能會略有不同,但董事會成員始終是內部人員。管理層最終向董事會負責。然而,如果管理人員是創始人或CEO,那麼成爲執行董事會成員也是很常見的。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多數人認爲內部所有權是積極的,因爲它可以表示董事會與其他股東的利益相一致。但是,在某些場合下,這個團體的權力過於集中。
Our information suggests that insiders maintain a significant holding in Joinn Laboratories(China)Co.,Ltd.. It has a market capitalization of just CN¥9.1b, and insiders have CN¥3.5b worth of shares in their own names. That's quite significant. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.
我們的信息顯示,內部人士在昭衍新藥(中國)股份有限公司中持有大量股份。它的市值僅爲91億元人民幣,內部人士有價值35億元人民幣的股份。這相當重要。大多數人會說,尤其是在這樣一個規模的公司中,這顯示了與股東的良好一致性。您可以點擊這裏查看內部人士是否有買賣。
General Public Ownership
一般大衆所有權
The general public, who are usually individual investors, hold a 42% stake in Joinn Laboratories(China)Co.Ltd. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
一般公衆,通常是個人投資者,持有昭衍新藥(中國)股份有限公司42%的股份。儘管這種所有權規模可能不足以左右政策決策對他們的青睞,但他們仍然可以對公司政策產生集體影響。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that Joinn Laboratories(China)Co.Ltd is showing 1 warning sign in our investment analysis , you should know about...
雖然考慮到公司的不同股東群體是非常值得的,但還有其他更重要的因素需要考慮。請注意,昭衍新藥(中國)有限公司在我們的投資分析中顯示出了1個警告信號,您應該知道...
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果您像我一樣,可能希望考慮這家公司是否會增長或縮小。幸運的是,您可以查看此免費報告,顯示分析師對其未來的預測。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。